Centessa Pharmaceuticals (NASDAQ:CNTA) Posts Earnings Results, Misses Estimates By $0.10 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) posted its quarterly earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10), FiscalAI reports.

Centessa Pharmaceuticals Price Performance

CNTA traded up $12.14 on Tuesday, hitting $39.72. 47,743,869 shares of the company were exchanged, compared to its average volume of 1,505,304. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The firm has a market capitalization of $5.80 billion, a P/E ratio of -21.70 and a beta of 1.55. The business’s fifty day moving average is $26.29 and its 200 day moving average is $25.24.

Insider Activity

In other news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 349,073 shares of company stock worth $9,429,412. Company insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. boosted its position in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares in the last quarter. Coastal Bridge Advisors LLC increased its holdings in Centessa Pharmaceuticals by 7.1% during the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after acquiring an additional 931 shares in the last quarter. XTX Topco Ltd purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $1,978,000. Voloridge Investment Management LLC acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth about $8,710,000. Finally, Virtus Investment Advisers LLC lifted its holdings in shares of Centessa Pharmaceuticals by 6.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after purchasing an additional 583 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CNTA. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Needham & Company LLC restated a “hold” rating on shares of Centessa Pharmaceuticals in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Centessa Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Key Stories Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.